Antios Therapeutics’ Record-Breaking Year

SEBIO 2019 > 2019 News > Antios Therapeutics’ Record-Breaking Year

Antios Logo

Antios Therapeutics’ Record-Breaking Year

August 21, 2019 | 2019 News

Dr. Abel De La Rosa, CEO of Atlanta-based Antios Therapeutics and Gerry Brunk, Managing
Director of Lumira Ventures, will hold a fireside chat to discuss the founding story of Antios, the
role of creative thinking in the discovery of new drugs and lessons learned from building
transformative biotechnology companies in the Southeast.

Antios is developing its lead oral drug candidate for a potentially curative treatment of Hepatitis B
infections, a major unmet global health problem affecting over 250 million people worldwide, and
a leading cause of chronic hepatitis, liver cirrhosis and liver cancer. Antios completed a $25M
oversubscribed Series A financing in 2018, the largest Series A financing ever for a Georgiabased
biotechnology company.

Before co-founding Antios Dr. De La Rosa was the Chief Scientific Officer of Drug Innovation
Ventures at Emory (DRIVE) and the Emory Institute for Drug Development (EIDD), focused on
the discovery and development of antiviral drugs for the treatment of viral diseases of unmet
medical need and global concern. Prior to joining Emory, he was Senior Vice President of
Business Development and Scientific Affairs at Pharmasset where, from 2002 until its acquisition
by Gilead Sciences for $11 billion in 2012, he was responsible for strategic transactions and
provided business and scientific leadership to drug development programs for the treatment of
HIV, Hepatitis B and Hepatitis C, including Sofosbuvir, the landmark curative therapy for
Hepatitis C.